Alberto Lleó Bisa

Alberto Lleó

Dr. Alberto Lleó is the director of the Memory Unit of the Neurology Department at Hospital de la Santa Creu i Sant Pau.

After obtaining his Medical degree from the University of Barcelona, he completed his specialization in Neurology at Hospital de la Santa Creu i Sant Pau in 2000. Two years later, he obtained his PhD in Medicine at the University of Barcelona and continued his education with a clinical and basic research fellowship on memory and movement disorders at the Massachusetts General Hospital, Boston (2002-2004) where he combined clinical and research tasks.

In his professional career, Dr. Alberto Lleó has combined his clinical activity with translational research projects in the field of dementias with a specific focus on the molecular bases of the disease and biomarker development. Some of his main contributions are the discovery of new genetic alterations in Alzheimer’s disease, the study of the gamma-secretase complex, and the assessment of new chemical biomarkers for Alzheimer’s disease and frontotemporal dementia.

Today, Dr. Alberto Lleó runs a translational group, leads many projects funded by public and private agencies, and collaborates regularly with numerous national and international research groups. He also coordinates the Alzheimer program of CIBERNED (Center for Networked Biomedical Research in Neurodegenerative Diseases). To date, he has authored more than 20 book chapters and over 150 publications in international journals, and his contributions have been awarded by the Spanish Society of Neurology.

Recent Publications

  1. Has the time arrived for cerebrospinal fluid biomarkers in psychiatric disorders?. Lleó, A, Parnetti, L, Belbin, O et al. Clin. Chim. Acta 2019
    PMID:30682327

  2. Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [18F]-Flutemetamol PET Scan Result. Westwood, S, Baird, AL, Hye, A et al. Front Aging Neurosci 2018
    PMID:30618716

  3. Changes in synaptic proteins precede neurodegeneration markers in preclinical Alzheimer's disease cerebrospinal fluid. Lleó, A, Núñez-Llaves, R, Alcolea, D et al. Mol. Cell Proteomics 2019
    PMID:30606734

  4. Decreased circulating ErbB4 ectodomain fragments as a read-out of impaired signaling function in amyotrophic lateral sclerosis. Lopez-Font, I, Sogorb-Esteve, A, Javier-Torrent, M et al. Neurobiol. Dis. 2019
    PMID:30594809

  5. HTT gene intermediate alleles in neurodegeneration: evidence for association with Alzheimer's disease. Menéndez-González, M, Clarimón, J, Rosas-Allende, I et al. Neurobiol. Aging 2018
    PMID:30583877

  6. Impact of CSF storage volume on the analysis of Alzheimer's disease biomarkers on an automated platform. Delaby, C, Muñoz, L, Torres, S et al. Clin. Chim. Acta 2019
    PMID:30579960

  7. LRP10 in α-synucleinopathies. Guerreiro, R, Orme, T, Neto, JL et al. Lancet Neurol 2018
    PMID:30507384

  8. Identification of evolutionarily conserved gene networks mediating neurodegenerative dementia. Swarup, V, Hinz, FI, Rexach, JE et al. Nat. Med. 2019
    PMID:30510257

  9. A comprehensive screening of copy number variability in dementia with Lewy bodies. Kun-Rodrigues, C, Orme, T, Carmona, S et al. Neurobiol. Aging 2019
    PMID:30448004

  10. Obesity and Alzheimer's disease, does the obesity paradox really exist? A magnetic resonance imaging study. Pegueroles, J, Jiménez, A, Vilaplana, E et al. Oncotarget 2018
    PMID:30410669

  11. Prevalence of Sleep Disorders in Adults With Down Syndrome: A Comparative Study of Self-Reported, Actigraphic, and Polysomnographic Findings. Giménez, S, Videla, L, Romero, S et al. J Clin Sleep Med 2018
    PMID:30353801

  12. Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimer's Disease Cerebrospinal Fluid Biomarkers. Ramos de Matos, M, Ferreira, C, Herukka, SK et al. J. Alzheimers Dis. 2018
    PMID:30320580

  13. Elevated YKL-40 and low sAPPβ:YKL-40 ratio in antemortem cerebrospinal fluid of patients with pathologically confirmed FTLD. Alcolea, D, Irwin, DJ, Illán-Gala, I et al. J. Neurol. Neurosurg. Psychiatry 2019
    PMID:30297518

  14. CSF sAPPβ, YKL-40, and NfL along the ALS-FTD spectrum. Illán-Gala, I, Alcolea, D, Montal, V et al. Neurology 2018
    PMID:30291183

  15. Prevalence of amyloid-β pathology in distinct variants of primary progressive aphasia. Bergeron, D, Gorno-Tempini, ML, Rabinovici, GD et al. Ann. Neurol. 2018
    PMID:30255971

Search PubMed